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Abstract
Background: Dengue virus infection is a growing global public health concern in tropical and subtropical regions of the
world. Dengue vaccine development has been hampered by concerns that cross-reactive immunological memory elicited
by a candidate vaccine could increase the risk of development of more severe clinical forms. One possible strategy to reduce
risks associated with a dengue vaccine is the development of a vaccine composed of selected critical epitopes of each of the
serotypes.
Methodology/Principal Findings: Synthetic peptides were used to identify B-cell epitopes in the envelope (E) glycoprotein
of dengue virus type 3 (DENV-3). Eleven linear, immunodominant epitopes distributed in five regions at amino acid (aa)
positions: 51–65, 71–90, 131–170, 196–210 and 246–260 were identified by employing an enzyme- linked immunosorbent
assay (ELISA), using a pool of human sera from dengue type 3 infected individuals. Peptides 11 (aa51–65), 27 and 28 (aa131–
150) also reacted with dengue 1 (DENV-1) and dengue 2 (DENV-2) patient sera as analyzed through the ROC curves
generated for each peptide by ELISA and might have serotype specific diagnostic potential. Mice immunized against each
one of the five immunogenic regions showed epitopes 51–65, 131–170, 196–210 and 246–260 elicited the highest antibody
response and epitopes131–170, 196–210 and 246–260, elicited IFN-c production and T CD4+ cell response, as evaluated by
ELISA and ELISPOT assays respectively.
Conclusions/Significance: Our study identified several useful immunodominant IgG-specific epitopes on the envelope of
DENV-3. They are important tools for understanding the mechanisms involved in antibody dependent enhancement and
immunity. If proven protective and safe, in conjunction with others well-documented epitopes, they might be included into
a candidate epitope-based vaccine.
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Dengue infections occur in the most of tropical and subtropical
areas of the world, and are considered as one of the most
important re-emerging disease [1]. More than 2.5 billion people
live in areas at risk of dengue infection and more than 100
countries have endemic dengue transmission [2]. Dengue virus is a
member of the family Flaviviridae, genus Flavivirus with four
antigenically distinct serotypes (DENV-1 to DENV-4). Dengue is
a single-stranded, positive-sense, RNA virus with a genome of
approximately 11 kb and it encodes three structural (Capsid, C;
pre-membrane, prM and envelope, E) and seven nonstructural
(NS) proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5) [3].
The E glycoprotein is exposed on the surface of the dengue virion
particle and is responsible for virus attachment, virus-specific
membrane fusion and virus assembly [4]. The E glycoprotein is
the most relevant B-cell antigen, conferring protective immune
responses by eliciting neutralizing antibodies and also no-
neutralizing antibodies, which can be involved in enhancement
of virus infection. The flavivirus E-glycoprotein contains three
structural and functional domains: domains I and III contain
predominately subcomplex and type-specific epitopes, whereas
domain II contains the major flavivirus group and subgroup cross-
reactive epitopes [5]. There is no available antiviral therapy to
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has proved elusive [6]. One ideal strategy to develop an effective
and safe dengue vaccine is the design of an epitope-based vaccine
containing selected immunogenic targets correlated with protec-
tion and devoid the ones associated with pathogenic reactions.
Epitopes in the E-glycoprotein [7–10], NS1 [11–13], NS4a and
capsid [3] for DENV-1 and DENV-2 have been mapped.
However, only few linear immunogenic determinants on the
surface of the virion of each dengue serotype have been identified
and a detailed map of the dengue linear B-cell epitopes still need to
be determined [14]. Most known neutralizing epitopes are
conformational, however continuous amino acid sequences
corresponding to antigenic determinants of the proteins that elicit
antibodies in dengue-infected patients are more suitable for
protein engineering and vaccine development. In particular, not
much information is available in the literature regarding the B-cell
epitopes in the proteins of DENV-3 [15]. In the present study, we
have screened for B cell epitopes in the E glycoprotein of DENV-3
recognized by serum of humans infected with DENV-3 and have
identified several immunodominant IgG-specific epitopes.
Materials and Methods
Peptide synthesis
A total of ninety-five peptides (each with 15-mers, overlap of 10)
were synthesized by Synpep Laboratory, California-USA. They were
produced covering the 490 amino acids (aa) of the E protein sequence
deducted from the genome of a Dengue 3 isolated from Brazil [16].
For convenience, this sequence will be cited as DENV-3seq. At first,
these peptides were used to perform first screening with pool of
patient sera. For screening using different groups of patients with
dengue fever (DF), dengue hemorrhagic fever (DHF) and patients
with DENV-1 or DENV-2 infections, the synthetic peptides were
used in a purest form (Schafer Laboratory, Copenhagen-DK),
covering all amino acids of the envelope protein. All synthetic
peptides used were similar and the only difference between them was
the Laboratory (Synpep or Schafer) where they were synthesized.
Hydropathicity, surface accessibility and antigenicity
analysis
DENV-3seq was analyzed using Lasergene software (DNAS-
TAR Inc.) and putative hydrophobic and hydrophilic regions
along the length predicted using Kyte and Doolittle method [17].
Surface accessibility and antigenicity analysis were done using
Emini [18] and [19] prediction methods respectively, both
available at ‘‘Immune Epitope Database and Analysis Resource’’
home page (www.immunoepitope.com). Other surface accessibility
prediction was done with DSSP program [20].
Modeling DENV-3seq E-glycoprotein
The homology modeling of DENV-3seq structure was done
using the First Approach Mode under the Swiss Model program
(www.swissmodel.expasy.org//SWISS-MODEL.html) [21] and
the Deep Viewer/Swiss PBD Viewer program was required for
visualization (www.expasy.org/spdbv/) [22].
Dengue patient sera
For the first screening using synthetic peptides, sera from eight
patients that were positive for anti-dengue serotype 3 antibodies were
pooled together and used as positive control. The diagnostic of these
patients were performed for IgM (anti-dengue IgM-capture ELISA, Bio-
manguinhos, Fundac ¸a ˜o Oswaldo Cruz, Brazil) and IgG antibodies (anti-
dengue IgG- ELISA, PanBio, Pty., LTd., Brisbane, Australia and in house
indirect anti-dengue IgG-ELISA). As negative control, peptides were
screened with a serum pool from twenty-one individuals that were
determined to be negative for DENV-3, and also for DENV-1 and
DENV-2 by multiple serological detection methods. The Virology
Branch of the Public Health Central Laboratory of Pernambuco
(LACEN-PE) provided pooled sera for the standard control (negative
and positive controls). The peptides mapped in this first screening
were used for testing individually sera from thirty-two positive
patients and seventeen dengue naive individuals, in order to
investigate the capacity of the epitopes in discriminate between
serum DENV-3 patients from non-dengue patients. The patient
serum samples were obtained from a dengue cohort developed at the
Virology and Experimental Therapy Laboratory (LAVITE), of the
Aggeu Magalha ˜es Research Center Recife, Brazil described
elsewhere [23]. The sera for DENV-3 were identified as positive
through conventional laboratory assays such as viral isolation, RT-
PCR, IgM and IgG antibodies detection. The normal sera were
defined as those who presented to be negative for IgM and IgG anti-
dengue antibodies. To investigate the power of the first mapped
peptides in discriminate the infections of DENV-3 from that of other
dengue serotypes, sera from twenty patients with defined DENV-1 or
DENV-2 infections, diagnosed as positive during 1999 Brazilian’s
dengue outbreak were used, provided by Virology Branch of the
Public Health Central Laboratory of Pernambuco (LACEN-PE).
Ethical considerations
Written consent to participate in the study was obtained from
each patient (or the patient’s guardian) after a full explanation of
the study was provided. All data were handled confidentially and
anonymously. This study was reviewed and approved by the ethics
committee of the Brazilian Ministry of Health (Nu 4909 CONEP)
and The Johns Hopkins University School of Medicine internal
review board (# 03-08-27-01).
Immunogenicity of human DENV-3 envelope B cell
epitopes on Balb/c mice
Balb/c mice were purchased from Jackson Laboratories (Maryland,
USA) and maintained in a helicobacter-negative environment at the
Johns Hopkins School of Medicine Animal Facility. Mice were divided
in six groups (two animals per group), whereby five groups represented
each of the five dengue E-glycoprotein epitope regions found on
human cohort, whereas the sixth group was the negative control. The
animals were immunized subcutaneously (base of the tail) twice, three
weeks apart, with total amount of peptide of 50 mg, emulsified in
TiterMax, per epitope region. When the epitope region was composed
of two or more peptides, they were polled together so that the final
amount of peptides injected was 50 mg. The epitope regions and the
peptide sequences analyzed are described below: (a) 51–65
(TQLATLRKLCIEGKI); (b) 71–90 [DSRCPTQGEAVLPEE (71–
85) and TQGEAVLPEEQDPNY (76–90)]; (c) 131–170 [QYENLK-
YTVIITVHT (131–145), KYTVIITVHTGDQHQ (136–150),
ITVHTGDQHQVGNET (141–155), GDQHQVGNETQGVTA
(146–160), VGNETQGVTAEITPQ (151–165) and QGVTAEITP-
QASTTE (156–170)]; (d) 196–210 (LLTMKNKAWMVHRQW);
and (e) 246–260 (PEVVVLGSQEGAMHT). The negative control
animals were immunized with aqueous solution of Titermax. The sera
of immunized mice and controls were collected before immunization,
three weeks after priming and two weeks after boosting for humoral
and cellular immune response analysis.
ELISA (enzyme linked immunosorbent assay) for peptide
epitope identification
ELISA was optimized using Synpep linear synthetic peptides
from E-glycoprotein. Briefly, each microtiter well (Immulon II,
DENV-3 Envelop B-Cell Epitopes
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4uC with 20 mg/ml in 100 ml/well of synthetic peptides in 0.2 M
carbonate buffer (CB), pH 9.6. Wells were then blocked with
200 ml of 5% dry skimmed milk in CB for 2 h at room
temperature (RT). The wells were washed in 0.05% Tween 20
(Reagen, RJ, Brazil) in phosphate buffered saline (PBS), pH 7.2,
and then 1:50 human sera diluted in 10% dry skimmed milk in
PBS was added and incubated for 1 h at 37uC. Another wash
followed with 0.05% Tween 20 in PBS and wells were incubated
for 2 h at RT with 100 ml of 1:1,000 peroxidase mouse anti-
human IgG monoclonal antibody (Zymed Laboratories Inc., CA-
USA), diluted in 10% dry skimmed milk in PBS. Finally, the
enzyme activity was detected with the addition of 100 mlo f
tetramethylbenzydine (TMB) substrate solution at 30 min in RT.
Optical densities (ODs) were measured at 450 nm in the microtiter
plate reader (Bio-Rad Benchmark Plus). As an internal positive
reference control, total cellular extract of DENV-3 infected cells
was used as the capture antigen [24].
ELISA for assessment of immunogenicity of envelope B
cell epitopes on Balb/c mice
For epitope validation on sera collected from peptide-immu-
nized Balb/c, Nunc microplates were coated with 100 mg/ml of
peptides (100 ul/well) diluted in carbonate/bicarbonate buffer
pH 9.6 and incubated overnight at 4uC. After washing with PBS
pH 7.2 containing 0.05% Tween 20 (PBS-T) the plates were
blocked with 5% BSA (bovine serum albumin, Sigma) in PBS
pH 7.2 for 1 h at 37uC. Then, the plates were washed and
incubated 2 h at 37uC with serially diluted sera (from 1:100 to
1:10,000,000) in dilution buffer (BSA 0.1% in PBS pH 7.2). The
samples were analyzed in duplicate. As a negative control (NC),
the same diluted sera were incubated in uncoated wells. The plates
were washed and incubated for 45 minutes at 37uC with a HRP
(horseradish peroxidase) -conjugated goat anti-Mouse IgG (Fab)2
(Jackson Immunoresearch) diluted 1,000-fold in dilution buffer.
Then, the plates were washed, developed with TMB (BD
Biosciences) and read at 450 nm in a microplate reader (Safari2,
Tecan).
ELISPOT (enzyme linked immunosorbent spot) assay
The IFN-c ELISPOT assay was performed by use of the
ELISPOT set (BD-Biosciences Pharmingen, San Diego, CA) as
described by the manufacturer. Briefly, PVDF (polyvinylidene
fluoride) plates were coated with mAb (monoclonal antibody) to
mouse IFN-c (5 mg/mL) diluted in PBS and incubated at 4uC
overnight. The plates were washed and blocked with RPMI 1640
containing 10% FBS (fetal bovine serum) for 2 hs at room
temperature (RT). Splenocytes were harvested from each mice
group as described above, being plated in three different ways: (i)
as total cells; (ii) as CD4+ T cell depleted splenocytes (CD8+ T cell
enriched sample); and (iii) CD8+ T cell depleted splenocytes
(CD4+ T cell enriched sample). CD4+ and CD8+ T cell depletions
were performed by using immune-magnetic beads coated with
antibodies (Abs) to CD4+ and CD8+, respectively, and depletion
columns according to manufacturer’s protocol (Miltenyi Biotec).
One hundred mL of cell suspension, containing in a range of
0.3610
6 to 1610
6 cells were added to wells containing 100 mLo f
peptides representing each epitope region identified in humans at
a final concentration of 10 mg/mL. Concanavalin A (Sigma-
Aldrich, St. Louis, MO), 5 mg/ml, and culture medium were used
as positive and negative controls, respectively. Plates were
incubated overnight at 37uC, in 5% CO2, washed with PBS-T
(PBS containing 0.05% Tween 20), and incubated with biotiny-
lated anti-mouse IFN-c (2 mg/ml) for 2 h at RT. After washing
step, the plates were incubated with 100-fold diluted streptavidin-
HRP for 1 h at RT, followed by washing and incubation with 3-
amino-9-ethylcarbazole substrate for 20 min at RT. The reaction
was stopped with distilled water. After the plates were air-dried,
the spots were counted by using a CTL analyzer, with the
ImmunoSpotH software. The average number of spot forming cells
(SFC) was normalized to 1610
6 splenocytes. The results were
considered significant when the average experimental SFC less 2
standard deviation (SD) was greater than the average of the
background plus 2 SD and the average of the experimental
peptides was greater than 10 SFCs per 10
6 cells.
Mapping B cell epitopes
For the purpose of first assigning the peptide determinants
reactive with patient serum, all ninety five peptides provided by
Synpep were tested for the positive and negative pool of sera as
described above. The mean OD obtained using negative sera pool
plus three times standard deviation was used as the cut-off value.
The most reactive peptides found at this first screening were tested
with the individual patients sera and the results were expressed in
ELISA arbitrary unity form (EAU), consisting in the ratio between
the OD found for each tested sample and the OD found for the
positive reference control (a total cellular extract of DENV-3
infected cells) [24] in the same plate, in order to minimize the
variability of positive and negative controls, as well as of the
samples in each assay.
Statistical Analysis
Medcalc version 8.2 was used for (receiver operating charac-
teristic) ROC analysis, plotting and determination of the cut-off.
ROC plot displayed sensitivity versus 1-specificity, such that the
areas under the curve (AUCs) generated varied from 0.5 to 1.0,
with higher values indicating increased discriminatory ability.
When the variable under study cannot distinguish between two
groups, the area will be equal to 0.5 (the ROC curve will coincide
with the diagonal). The cut-off was selected to yield the highest
accuracy to discriminate DENV-3 and non-dengue infections or
other serotypes infections (minimal false negative and false positive
results). Comparisons of AUCs were performed using non-
parametric assumptions. Sensitivity, specificity using a confidence
interval of 95% for each one of the eleven peptides were calculated
and the differences were considered significant if P,0.05.
Results
Identification of E-glycoprotein epitopes
The ELISA results showed that the human dengue serum
reacted with eleven peptides along the entire length of the E-
glycoprotein molecule. These results are shown in the main panel
of Figure 1. These peptides are distributed in five continuous
regions at amino acid positions 51–65, 71–90, 131–170, 196–210
and 246–260. The sequences of these peptides and their relative
epitope activity are summarized in Table 1.
Analyzing hydropathicity, surface accessibility and
antigenicity profiles
Parameters such as hydrophilicity, flexibility, accessibility, turns
and antigenicpropensity of polypeptideschain have been correlated
with the location of continuous epitopes. This has led to a search for
empirical rules that would allow the position of continuous epitopes
to be predicted from certain features of the protein sequence. The
evaluation of DENV-3seq, showed that all eleven peptides are in
hydrophilic areas according to Kyte and Doolittle hydropathy
profiles suggesting that these regions are exposed at the surface of
DENV-3 Envelop B-Cell Epitopes
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three peptides from eleven, those including residues VQYENLK
(aa130–136)and TGDQHQVGNETQ(aa 145–156),appearingto
be really exposed in the protein surface. In the antigenicity
prediction was found that six peptides, those spanning the
residues TQLATLRKLCIEG (aa 51–63), QGEAVLPE (aa
77–84), EGKVVQYENLKYTVIITVHTG (aa 126–146) and
KKPEVVVLGS (aa 244–253) were considered the most antigenic.
Modeling DENV-3seq
The amino acid sequence of the DENV-3seq was sent to the
First Approach Mode under the Swiss Model server [21]. The
Swiss Model server returned a monomer of the DENV-3 seq
structure based on homology modeling with the published DENV-
3 crystal structure (1UZG.pdb, 95.9% of sequence identity) [6]
deposited in the Protein Data Bank- PDB [25]. Since the DENV-3
E-glycoprotein molecule consists of a dimer, just for illustrative
purposes, a dimer of DENV-3seq structure was built by
superimposing the two monomers on the dimer consisting the
structure 1UZG.pdb using Deep View/Swiss-PdbViewer program
version 3.7/SP5 [22]. The homology model based on the structure
1UZG.pdb also lacks 101 amino acids (positions 558 to 659) which
have not been crystallized within the published DENV-3. Figure 2
is shown for illustrative purposes only and a better refinement to
predict the exact dimer formation and carbohydrate composition
should be taken into consideration. The Swiss Model server is only
based on the amino acid sequence of the protein, therefore correct
carbohydrate orientation would have been difficult to predict
without further analysis. The dimer in Figure 2, shows the position
of the eleven mapped peptides in the E-glycoprotein structure, in
different colors.
Analyzing the reactivity profile of eleven mapped
peptides to discriminate the infections between DENV-3,
other dengue serotypes (DENV-1 and DENV-2) and non-
dengue patients
The results were analyzed through the ROC curves generated
for each peptide. The ability of the antibody response to
discriminate the serum from an infected person from an individual
that was not exposed to the dengue virus was evaluated using
ROC curve analysis, which can also be used to compare the
diagnostic performance of two or more tests. ROC curve is a
graphical plot of the sensitivity versus (1-specificity) for a binary
classifier system as its discrimination threshold is varied. The
accuracy can be measured by the area under the curve (AUC).
Table 1. Immunoreactive DENV- 3 E-glycoprotein peptides.
Peptide
# Peptide sequence (aa residue #s)
ELISA(OD450)
Human sera
11 TQLATLRKLCIEGKI (51–65) 0,90
15 DSRCPTQGEAVLPEE (71–85) 0,59
16 TQGEAVLPEEQDPNY (76–90) 0,55
27 QYENLKYTVIITVHT (131–145) 0,72
28 KYTVIITVHTGDQHQ (136–150) 0,87
29 ITVHTGDQHQVGNET (141–155) 0,82
30 GDQHQVGNETQGVTA (146–160) 0,75
31 VGNETQGVTAEITPQ (151–165) 0,76
32 QGVTAEITPQASTTE (156–170) 0,78
40 LLTMKNKAWMVHRQW (196–210) 1,03
50 PEVVVLGSQEGAMHT (246–260) 0,72
ELISA; enzyme linked immunosorbent assay.
OD; optical densities.
doi:10.1371/journal.pone.0007425.t001
Figure 1. IgG-specific activities of synthetic peptides of DENV-3 E-glycoprotein, using human sera. The horizontal axis denotes the
peptide number and the vertical axis denotes the absorbance measured at 450 nm. The cut-off absorbance used to identify reactive epitopes is
shown by the red line. Ag, antigen; Peps, peptides; B, blank; C+, positive control; C-, negative control.
doi:10.1371/journal.pone.0007425.g001
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area is 1.0, you have an ideal test, because it achieves both 100%
sensitivity and 100% specificity. If the area is 0.5, then you have a
test, which has effectively 50% sensitivity and 50% specificity. The
closer the area is to 1.0, the better the test is to discriminate in this
case, the infections between DENV-3 and non-dengue patients
and between DENV-3 and infections for other dengue serotypes
(DENV-1 and DENV-2). AUC significantly different of 0.5
(P,0.05) indicates the power of the peptides to discriminate
between the studied groups. The peptides indentified in the first
screening were used for testing individually sera from thirty-two
positive patients and seventeen dengue naive individuals, in order
to investigate the capacity of the epitopes in discriminate between
serum DENV-3 patients from non-dengue patients. The assays
demonstrates that peptides 15, 16, 28, 29, 30, 31, 32, 40 and 50
have some power to discriminate between DENV-3 infections and
non dengue (Table 2 and Figure 3A), with likely potential for using
in the diagnostic assays for DENV-3 infections, on the contrary of
peptides 11 and 27, that did not perform well. To investigate if the
epitopes could discriminate the infections of DENV-3 from that of
other dengue serotypes, we assayed the sera from twenty patients
with defined DENV-1 or DENV-2 infections. The AUC showed
that peptides 11, 27 and 28 (Table 3 and Figure 3B) presented
significant performances discriminating the dengue serotype. In
this case, patients with DENV-1 and 2 serotypes infections
answered to peptides 11, 27 and 28 with higher OD levels than
patients with DENV-3.
Immunogenicity of Human DENV-3 Envelope B and T cell
Epitopes on Balb/c Mice
In order to see whether the epitope regions identified in the
human cohort were capable to elicit immune response in animal
model, Balb/c mice were immunized against each immunogenic
region and the immune response was assessed (see methods for
detail). The Figure 4 depicts level of total specific IgG in different
dilution for each peptide either after priming or boosting. The
regions 51–65 (Figure 4A), 131–170 (Figure 4C) and 196–210
(Figure 4D) elicited IgG response after both time points analyzed,
whereas the region 246–260 (Figure 4E) elicited IgG response only
after boosting. The magnitude of production seemed to be as
follow: 51–65.131–170.196–210.246–260. The region 71–90
(Figure 4B), was the only one which did not elicit any IgG response
in this mice model. IFN-c production by total splenocytes as well
as CD8+ or CD4+ T enriched cells was also evaluated through
ELISPOT assay for IFN-c on immunized mice and controls.
Among the regions analyzed epitopes 131–170, 196–210 and 246–
Figure 2. Top view of the homology model of the DENV-3seq E-glycoprotein dimer and location of the eleven mapped peptides.
Peptides are represented in colorful space-filling: peptide 11 in green, peptides 15 and 16 in orange, peptides 27, 28, 29, 30, 31 e 32 in blue, 40 in red
and 50 in violet. For illustrative reasons one monomer is represented as space-filling and the other as ribbons.
doi:10.1371/journal.pone.0007425.g002
Table 2. Performance of E protein peptides to discriminate
dengue infections: DENV-3 infections and non-dengue.
Peptides CO Sens. Spec. AUC 95% CI p value
11 0,139 59,4 58,8 0,566 0,417–
0,707
0,4385
15 0,379 46,9 94,1 0,718 0,571–
0,837
0,0030
16 0,372 65,6 94,1 0,835 0,701–
0,925
,0,0001
27 0,272 28,1 94,1 0,528 0,381–
0,673
0,7428
28 0,231 56,2 88,2 0,738 0,593–
0,853
0,0008
29 0,461 68,7 88,2 0,767 0,625–
0,876
0,0001
30 0,461 65,6 94,1 0,813 0,676–
0,910
,0,0001
31 0,445 68,7 94,1 0,836 0,703–
0,926
,0,0001
32 0,419 81,2 94,1 0,869 0,742–
0,948
,0,0001
40 0,189 84,4 94,1 0,831 0,697–
0,923
,0,0001
50 0,232 90,6 94,1 0,907 0,789–
0,971
,0,0001
Sensibility (Sens.), specificity (Spec.), cut-off (CO) and area under curve (AUC)
generated for each one of the eleven peptides in the ROC curve. Confidence
interval (CI) and p value are shown.
doi:10.1371/journal.pone.0007425.t002
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Depletion assays revealed that all T cell response seen was
exclusively T CD4+ (Figure 5).
Discussion
Dengue represents the most important arthropod-borne viral
disease in humans in terms of morbidity and mortality and at the
present there is no one antiviral therapy available. Although
vaccine development is an undisputed public health priority, it
remains a considerable scientific challenge due to the four
antigenically distinct serotypes and possible risk factors associated
to vaccination and disease severity [26]. One possible strategy to
avoid pathogeny associated with a dengue vaccine would be to
design a vaccine composed of a selected set of epitopes from the
four serotypes. The majority of the epitopes involved in dengue
neutralization might be present in the E-glycoprotein, which is the
major surface protein in the viral particles [14].
Most dengue vaccine candidates and diagnostic methods
available nowadays, make use of some part of the E glycoprotein
and these peptides might be able to induce cellular and humoral
responses. An effective vaccine will need to elicit durable
neutralizing-antibody responses, [27] and it is known that mature
B-cell memory responses require cytokines from T helper (Th)
cells. Synthetic peptides prepared from the sequences of the
structural glycoproteins of several viruses have been evaluated for
Th cell activity [28]. However, the identification of B-cell epitopes
is also important for vaccine design, development of diagnostic
reagents and also for studies to elucidate the interactions between
virus and antibody on a molecular level [13].
The purpose of this study was to locate linear B-cell epitopes on
the dengue virus envelope glycoprotein, which might be
potentially useful in diagnosis, vaccine design and immunological
studies.
The ELISA results showed that the human serum from patients
reacted with eleven continuous peptides, IgG-specific, distributed
in five regions at amino acids positions 51–65, 71–90, 131–170,
196–210 and 246–260. Some immunogenic peptides have been
identified in the E-glycoprotein of DENV-1 and DENV-2, but not
much information is available about B-cell epitopes present in the
E-glycoprotein of DENV-3. In 2001 and 2005, some reports
Table 3. Performance of E protein peptides to discriminate
dengue infections: DENV-3 and dengue for other serotypes
infections.
Peptides CO Sens. Spec. AUC 95% CI p value
11 0,27 90,6 65,0 0,816 0,684–
0,909
,0,0001
15 0,331 43,7 85,0 0,614 0,469–
0,746
0,1634
16 0,826 93,7 20,0 0,530 0,387–
0,670
0,7144
27 0,34 87,5 80,0 0,851 0,725–
0,934
,0,0001
28 0,329 71,9 85,0 0,759 0,621–
0,867
0,0003
29 0,951 90,6 25,0 0,505 0,363–
0,646
0,9550
30 0,326 21,9 95,0 0,547 0,403–
0,685
0,5732
31 1,197 100,0 20,0 0,536 0,392–
0,675
0,6660
32 0,801 62,5 60,0 0,505 0,363–
0,646
0,9550
40 0,235 75,0 45,0 0,500 0,358–
0,642
1,00
50 0,318 78,1 40,0 0,493 0,325–
0,635
0,9326
Sensibility (Sens.), specificity (Spec.), cut-off (CO) and area under curve (AUC)
generated for each one of the eleven peptides in the ROC curve. Confidence
interval (CI) and p value are shown.
doi:10.1371/journal.pone.0007425.t003
Figure 3. ROC curves generated by Medcalc Software, 8.2 version. (A) Peptides 15, 16, 28, 29, 30, 31, 32, 40, 50 and its power to discriminate
between DENV-3 infections and non dengue. (B) Peptides 11, 27, 28 and its power to differentiate DENV-3 infection from dengue infection of other
serotypes.
doi:10.1371/journal.pone.0007425.g003
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of DENV-3 [6,14].
All the eleven peptides mapped are present in the hydrophilic
regions of the protein, suggesting that they could be exposed on
the surface of the E-glycoprotein. However, the interface between
monomers within a dimer is a mixture of hydrophobic (60%) and
hydrophilic (40%) interactions. So, peptides that appear to be
hydrophilic based on the prediction tools could not be accessible to
the antibody binding. The accessibility and antigenicity predic-
tions showed that from eleven, only three peptides (27, 29 and 30)
seems to be exposed at the surface and six (11, 15, 16, 27, 28 and
50) are the most antigenic. The homology modeling of the 3-D
structure shown in Figure 2 suggests that peptides 27, 29 and 30
(in blue) are being exposed in the molecule like loops projecting for
the surface. The peptide 50 (violet) is the most hidden in the dimer
interface but it appears as one of the most antigenic according to
the prediction. Peptide 11 (in green), despite being one of the most
antigenic does not seem to be the most exposed, according
Figure 2. The monomers in the E-glycoprotein make interactions
with each other and one of this region contact is on domain II
(residues 256–265), which interacts with the same residues across
the dyad axis [29]. Peptide 50, spanning residues 246–260, seems
to make part of this contact region between monomers.
The results presented demonstrate that was not possible to find
the exact location of the carbohydrates in the E-glycoprotein of
DENV-3seq, but asparagine (Asn) residues are found in peptides
29, 30 and 31, spanning amino acids 141-165. There are two
glycosylated asparagines on each dengue E subunit: Asn-153 on
domain I and Asn-67 on domain II. Asn-153 is conserved in most
flavivirus envelope proteins and bears a tetrasaccharide, where the
fourth sugar (a mannose), appears to be important for viral entry
[30].
The E-glycoprotein has three structural domains: DI (spanning
residues 130–185), DII (spanning residues 50–130 and 185–300)
and DIII (spanning residues 300–400). From the eleven mapped
peptides, those included at positions 51–65 (peptide 11), 71–90
(peptides 15 and 16), 196–210 (peptide 40) and 246–260 (peptide
50) are located on DII and those included on positions 131–170
Figure 4. Total IgG production in Balb/c mice elicited by envelope epitopes. (A) 51–65, (B) 71–90, (C) 131–170, (D) 196–210 and (E) 246–260
identified in naturally dengue-infected humans. Balb/c mice were immunized twice with different epitopes and the humoral immune response
(pooled sera, n=2 per group) was assessed through ELISA after priming and boosting in different serum dilutions. NC, negative control.
doi:10.1371/journal.pone.0007425.g004
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contains predominately type-specific non-neutralizing epitopes.
On the other hand, DII contains many cross-reactive epitopes
eliciting neutralizing and non-neutralizing monoclonal antibodies
that bind to fusion peptides, while DIII contains multiple type and
subtype specific epitopes and several conformational virus-
neutralizing epitopes [31,32]. Several additional studies focused
on the understanding of the biological properties of these epitopes
on protection (neutralization) or pathogenicity (antibody depen-
dent enhancement - ADE) are on going.
The E-glycoprotein is a class II fusion protein, typical of
flaviviruses and alphaviruses, where a proteolytic cleavage yields
mature virions with the fusion peptide primed for fusion. These
fusion peptides are a hydrophobic sequence conserved among all
flaviviruses and present on domain II (spanning residues at
positions 98–109 for DENV-2), hidden on the dimer interface and
becoming exposed during the conformational change initiated by
exposure to low pH [6,30,33]. The peptides 15–16 are adjacent to
the putative DENV3 fusion peptide regions and hence potentially
neutralizing. However, mapping to the fusion loop was not always
associated with therapeutic activity. Thus, has been demonstrated
that antibodies targeting this region could be protective against
infection in some cell types and possibly pathological in others
[32].
In this work, positive patient sera, with different types of viral
infections, and normal individual sera were tested against the
eleven mapped peptides, in order to evaluate their ability to
discriminate infections between DENV-3 and non-dengue patients
and between DENV-3 and infections for other dengue serotypes
(DENV-1 and DENV-2). It is important to note that there is no
DENV-4 circulation in our region; wherefore a study of a cross-
reactive response using sera from patients infected with this
serotype was not done due to the lack of available DENV-4
samples.
The results about the ability of the antibodies against the eleven
peptides in discriminating the dengue infections showed that
specific antibodies against the peptides 15, 16, 28, 29, 30, 31, 32,
40 and 50 can discriminate between DENV-3 and non-dengue
infections. These results indicated that these peptide epitopes
could be used as antigen in diagnostic kits. The evaluation of the
peptide epitopes in discriminating serological responses to DENV-
3 from other dengue serotypes (DENV-1 and DENV-2), showed
that peptides 11, 27 and 28 were able to differentiate these groups.
The reasons that patients previously exposed to DENV 1-2
serotypes produce a stronger antibody titer against these DENV 3
peptides are not clear. Maybe, these peptide regions are more
exposed or are more immunogenic in the context of the DENV-1
and DENV-2 E-glycoprotein. In the case of peptides 11 and 27 we
found that they are not responsive to DENV-3 when compared to
normal individuals (data not shown), so it might have a specific
diagnostic potential to DENV 1–2 serotypes. However more
studies are required to verify this assumption. On the other hand,
peptide 28 showed to be a promiscuous reactive peptide once it
reacted well with serum of all dengue patients (DENV-1–2 and 3).
It has been demonstrated that for a number of viruses, Th-cell
epitopes can be modeled using synthetic peptides and that active
Th-cell epitopes can modulate the antibody response from B-cell
epitopes. These observations are important in vaccine design and
mean that effective vaccines will most likely require co-expression
of B- and T-cell epitopes [34]. However, the results showed here
that peptide 27 despite of appearing in all predictions and
curiously also being a putative CD4+ T-cell epitope [35], does not
differentiate well between dengue 3 and non-dengue patient serum
but can be a potential candidate as a marker for serotype
diagnostic.
For further characterization of the DENV3 envelope regions
recognized by sera of naturally dengue-infected people, Balb/c mice
were immunized with each epitope and the humoral and cellular
immune responses were assessed. Four out of 5 dengue epitopes
identified in this report showed to be immunogenic in Balb/c mice.
The region 51–65 induced the strongest antibody response despite no
IFN-c response was detected in mice immunized with this epitope,
suggestingthat this immunizationmightbe eliciting humoralimmune
response in a T cell independent manner. The envelope epitopes
131–170, 196–210 and 246–260 elicited both IgG production and T
CD4-restricted response. The epitope 71–90 did not induce neither
humoral nor IFN-c response in this mice model. It’s quite interesting
that such small peptides (15-mer) can elicit not only T cell, but also B
cell response as shown in this report. Reynolds et al [36] recently
using an experimental autoimmune glomerulonephritis (EAG) model
have shown that WKY rat immunized with the 15mer pcol (24–38) -
(FTRHSQTTANPSCPE), a stretch of a human B cell epitope in the
N terminal of the alpha 3 chain of type IV collagen; elicited either
strong B cell or T cell response. Thus, we believe that as long as the
15-mer encompasses a B cell epitope, it can elicit both B and T cell
responses. Corroborating with that, Singh et al [37] reported that a
peptidesequenceassmallas12-merlongcouldprime forantibody,T
cell proliferative as well as for DHT response in different mice strain,
including Balb/c. Thus, the antibodies produced against these
15mers in Balb/c can be used to further analyze some properties of
these anti-serums, such as virus neutralizing activity.
Our study identified several immunodominant IgG-specific
epitopes on the envelope of DENV-3. The peptides of the E
glycoprotein described herein in conjunction with other well-
documented epitopes are potentially relevant for the development
of diagnostic reagents and a proposal to an effective vaccine for the
dengue virus.
Acknowledgments
We thank Dr. Carlos Brito for the clinical diagnosis of the DENV-3
patients and George Tadeu Diniz for the support on statistical analysis.
Figure 5. T-cell response through ELISPOT assay for IFN-c
elicited in Balb/c mice immunized with the envelope epitopes
identified in human. The T cell response was assessed using total
splenocytes harvested from immunized mice as well as from CD8+ T cell
enriched splenocytes (CD4+T cell-depleted) or CD4+ T enriched
splenocytes (CD8+ T cell -depleted). In asterisk are the groups
considered positive in all mice analyzed based upon the following
criteria: spot forming cells (SFC) less 2 standard deviation (SD) was
greater than the average of the background plus 2 SD; and the average
of the experimental peptides was greater than 10 SFCs per 10
6 cells.
The result shown is the average and standard deviation from two
different mice.
doi:10.1371/journal.pone.0007425.g005
DENV-3 Envelop B-Cell Epitopes
PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7425Author Contributions
Conceived and designed the experiments: ANMRdS EJNN FGCA SMLM
ETM. Performed the experiments: ANMRdS EJNN MTC. Analyzed the
data: ANMRdS EJNN MTC LHVGG FGCA SMLM ETM. Contributed
reagents/materials/analysis tools: MTC LHVGG FGCA ETM. Wrote the
paper: ANMRdS EJNN MTC SMLM ETM.
References
1. Yamada K, Takasaki T, Nawa M, Kurane I (2002) Virus isolation as one of the
diagnostic methods for dengue virus infection. J Clin Virol 24: 203–209.
2. Guzman MG, Kouri G (2004) Dengue diagnosis, advances and challenges.
Int J Infect Dis 8: 69–80.
3. Anandarao R, Swaminathan S, Khanna N (2005) The identification of
immunodominant linear epitopes of dengue type 2 virus capsid and NS4a
proteins using pin-bound peptides. Virus Res 112: 60–68.
4. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, et al. (1999)
Dengue virus structural differences that correlate with pathogenesis. J Virol 73:
4738–4747.
5. Crill WD, Chang GJ (2004) Localization and characterization of flavivirus
envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975–13986.
6. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in
the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79:
1223–1231.
7. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the
envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328.
8. Beasley DW, Aaskov JG (2001) Epitopes on the dengue 1 virus envelope protein
recognized by neutralizing IgM monoclonal antibodies. Virology 279: 447–458.
9. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, et al. (2001) Mapping
of a dengue virus neutralizing epitope critical for the infectivity of all serotypes:
insight into the neutralization mechanism. J Gen Virol 82: 1885–1892.
10. Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, et al. (2006)
Tetravalent neutralizing antibody response against four dengue serotypes by a
single chimeric dengue envelope antigen. Vaccine 24: 335–344.
11. Huang JH, Wey JJ, Sun YC, Chin C, Chien LJ, et al. (1999) Antibody responses
to an immunodominant nonstructural 1 synthetic peptide in patients with
dengue fever and dengue hemorrhagic fever. J Med Virol 57: 1–8.
12. Wu HC, Huang YL, Chao TT, Jan JT, Huang JL, et al. (2001) Identification of
B-cell epitope of dengue virus type 1 and its application in diagnosis of patients.
J Clin Microbiol 39: 977–982.
13. Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, et al. (2003) Identification of a
dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of
DEN-2-immunized animal serum samples using an epitope-based peptide
antigen. J Gen Virol 84: 2771–2779.
14. Serafin IL, Aaskov JG (2001) Identification of epitopes on the envelope (E)
protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch
Virol 146: 2469–2479.
15. Matsui K, Gromowski GD, Li L, Schuh AJ, Lee JC, et al. (2009)
Characterization of dengue complex-reactive epitopes on dengue 3 virus
envelope protein domain III. Virology 384: 16–20.
16. Miagostovich MP, dos Santos FB, de Simone TS, Costa EV, Filippis AM, et al.
(2002) Genetic characterization of dengue virus type 3 isolates in the State of Rio
de Janeiro, 2001. Braz J Med Biol Res 35: 869–872.
17. Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic
character of a protein. J Mol Biol 157: 105–132.
18. Emini EA, Hughes JV, Perlow DS, Boger J (1985) Induction of hepatitis A virus-
neutralizing antibody by a virus-specific synthetic peptide. J Virol 55: 836–839.
19. Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of
antigenic determinants on protein antigens. FEBS Lett 276: 172–174.
20. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern
recognition of hydrogen-bonded and geometrical features. Biopolymers 22:
2577–2637.
21. Schwede T, Kopp J, Guex N, Peitsch MC (2003) SWISS-MODEL: An
automated protein homology-modeling server. Nucleic Acids Res 31:
3381–3385.
22. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an
environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
23. Cordeiro MT, Silva AM, Brito CA, Nascimento EJ, Magalhaes MC, et al. (2007)
Characterization of a dengue patient cohort in Recife, Brazil. Am J Trop Med
Hyg 77: 1128–1134.
24. Hechavarria A (2002) Manual de procedimientos de te ´cnicas para el diagno ´stico
del dengue. Organizacio ´n Panamericana de la Salud, Republica de Nicara ´gua..
25. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The
Protein Data Bank. Nucleic Acids Res 28: 235–242.
26. Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, et al. (2005)
Review on flavivirus vaccine development. Proceedings of a meeting jointly
organised by the World Health Organization and the Thai Ministry of Public
Health, 26–27 April 2004, Bangkok, Thailand. Vaccine 23: 2689–2695.
27. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, et al. (2004) Safety
and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine
formulations in nonhuman primates. J Virol 78: 4761–4775.
28. Mathews JH, Allan JE, Roehrig JT, Brubaker JR, Uren MF, et al. (1991) T-
helper cell and associated antibody response to synthetic peptides of the E
glycoprotein of Murray Valley encephalitis virus. J Virol 65: 5141–5148.
29. Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, et al. (2004)
Conformational changes of the flavivirus E glycoprotein. Structure 12:
1607–1618.
30. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue
virus envelope protein after membrane fusion. Nature 427: 313–319.
31. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of
dengue virus E glycoprotein are the most efficient blockers of virus adsorption to
Vero cells. J Virol 75: 7769–7773.
32. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody
recognition and neutralization determinants on domains I and II of West Nile
Virus envelope protein. J Virol 80: 12149–12159.
33. Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, et al. (2003)
Visualization of membrane protein domains by cryo-electron microscopy of
dengue virus. Nat Struct Biol 10: 907–912.
34. Roehrig JT, Johnson AJ, Hunt AR, Beaty BJ, Mathews JH (1992) Enhancement
of the antibody response to flavivirus B-cell epitopes by using homologous or
heterologous T-cell epitopes. J Virol 66: 3385–3390.
35. Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V (2005) MULTI-
PRED: a computational system for prediction of promiscuous HLA binding
peptides. Nucleic Acids Res 33: W172–179.
36. Reynolds J, Haxby J, Juggapah JK, Evans DJ, Pusey CD (2009) Identification of
a nephritogenic immunodominant B and T cell epitope in experimental
autoimmune glomerulonephritis. Clin Exp Immunol 155: 311–319.
37. Singh B, Lee KC, Fraga E, Wilkinson A, Wong M, et al. (1980) Minimum
peptide sequences necessary for priming and triggering of humoral and cell-
mediated immune responses in mice: use of synthetic peptide antigens of defined
structure. J Immunol 124: 1336–1343.
{
DENV-3 Envelop B-Cell Epitopes
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7425